1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(2S)-3-oxopentan-2-yl]-1$l^{5}-pyridin-1-ylium

• ChemBase编号: 4004
• 分子式: C26H35N7O15P2
• 平均质量: 747.541522
• 单一同位素质量: 747.16663672
• SMILES: CCC(=O)[C@@H](C)c1cc[n+](cc1C(=O)N)[C@@H]1O[C@@H](COP(=O)([O-])O[P@](=O)(O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)n2cnc3c2ncnc3N)[C@H](O)[C@H]1O
• Canonical SMILES: CCC(=O)[C@H](c1cc[n+](cc1C(=O)N)[C@@H]1O[C@H]([C@@H]([C@H]1O)O)COP(=O)(O[P@@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O)n1cnc2c1ncnc2N)O)[O-])C
• InChI: InChI=1S/C26H35N7O15P2/c1-3-14(34)11(2)12-4-5-32(6-13(12)23(28)39)25-20(37)18(35)15(46-25)7-44-49(40,41)48-50(42,43)45-8-16-19(36)21(38)26(47-16)33-10-31-17-22(27)29-9-30-24(17)33/h4-6,9-11,15-16,18-21,25-26,35-38H,3,7-8H2,1-2H3,(H5-,27,28,29,30,39,40,41,42,43)/t11-,15-,16-,18-,19-,20+,21+,25+,26+/m0/s1
• InChIKey: BZJFKYRGSZWSLT-LCFZZZLDSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(2S)-3-oxopentan-2-yl]-1$l^{5}-pyridin-1-ylium
• IUPAC传统名: 1-[(2R,3R,4R,5S)-5-({[(S)-([(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-4-[(2S)-3-oxopentan-2-yl]-1$l^{5}-pyridin-1-ylium
• 别名: Nicotinamide Adenine Dinucleotide 3-Pentanone Adduct

登记号

• PubChem SID: 160967439; 46506591
• PubChem CID: 46936970

理论计算性质

JChem

• Acid pKa: -7.028098
• 质子受体: 16
• 质子供体: 7
• LogD (pH = 5.5): -9.939202
• LogD (pH = 7.4): -10.196176
• Log P: -9.250521
• 摩尔折射率: 164.9353 cm^3
• 极化性: 65.39102 Å^3
• 极化表面积: 338.16 Å^2
• 可自由旋转的化学键: 14
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.51
• LOG S: -2.65
• 溶解度: 1.81e+00 g/l

详细说明

DrugBank - DB04421

Drug information: experimental